PROGNOSIS IN COVID-13
https://doi.org/10.51922/1818-426X.2024.3.132
Abstract
Background. Identification and clarification of the role of clinical and laboratory indicators in assessing the unfavorable prognosis of COVID-19 is important, allowing to identify patients at risk at an early stage of the pathological process.
The purpose of this work was to identify clinical and laboratory predictors that influence worsening prognosis and mortality in COVID-19.
Materials and methods. The study was conducted at the 5th City Clinical Hospital in Minsk, which involved 240 patients with severe COVID-19.
Results. According to the results of the study, in the group of the deceased persons of older age group prevailed, the average index of comorbidity of pathologies in the group of the survivors was 2 pathologies (max 7, min 0), in the group of the deceased – 2 pathologies (max 10, min 0, Me 3), which had statistically significant difference at the level of p = 0.00006. Among complications, the most frequently recorded were DN 1–3 degree (in 84.87 % of surviving patients and 71.9 % of deceased patients), pulmonary edema (in 2.52 and 12.4 % of patients, respectively), SPON (in 5.88 and 19.83 % of patients, respectively). A decrease in SrO2 less than 93 % significantly reduced the chances of recovery (OR 0.422; 95 % CI 0.138–0.637). An elevated CRP level > 5 mg/L had a significant association with unfavorable COVID-19 outcome (OR 2.721; 95 % CI 1.342–6.657).
Conclusion: factors affecting prognosis in COVID-19 turned out to be older age, desaturation less than 93 % (χ2 = 245.211; p < 0.0001), high percentage of comorbidity p = 0.00006 (p < 0.05), leukocytosis (χ2 = 18.36; p < 0.001), increased levels of C-reactive protein (χ2 = 132.455; p < 0.001), procalcitonin, IL-6, D-dimers (χ2 = 161.122; p < 0.001).
References
1. Biomarkery tjazhesti techenija COVID-19: sravnenie sobstvennyh rezul’tatov s dannymi literatury / U. S. Plyaskina [et al.] // Effective Pharmacotherapy. – 2023. – Т. 19, № 27. – S. 6–14.
2. Osobennosti techenija COVID-19 u pacientov s soputstvujushhimi zabolevanijami. Obzornaja stat’ja / М. М. Iskakov [et al.] // Pharmacy of Kazakhstan. – 2022. – № 3. – S. 77–81.
3. Selitskaya, О. P. Sovremennye predstavlenija o klinicheskoj i laboratornoj harakteristike citokinovogo shtorma u pacientov s COVID-19 i vozmozhnosti ego intensivnoj terapii / О. P. Selitskaya, M. L. Dotsenko, S. S. Grachev // Recipe. – 2022. – Т. 25, № 6. – S. 821–834.
4. Analysis of factors affecting the prognosis of COVID-19 patients and viral shedding duration / J. Han [et al.] // Epidemiology and infection. – 2020. – Vol. 148. – P. e125.
5. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study / F. Zhou [et al.] // Lancet. – 2020. – Vol. 395, № 10229. – P. 1054–1062.
6. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients / K. Liu [et al.] // The Journal of infection. – 2020. – Vol. 80, № 6. – P. e14–e18.
7. Risk factors for disease severity, unimprovement, and mortality of COVID-19 patients in Wuhan, China / J. Zhang [et al.] // Clinical microbiology and infection. – 2020. – Vol. 26, № 6. – P. 767–772.
8. Weiss, P. Clinical course and mortality risk of severe COVID-19 / P. Weiss, D. R. Murdoch // Lancet. – 2020. – Vol. 395, № 10229. – P. 1014–1015.
Review
For citations:
Sialitskaya O.P. PROGNOSIS IN COVID-13. Medical Journal. 2024;(3):132-136. (In Russ.) https://doi.org/10.51922/1818-426X.2024.3.132
Views:
9
Email this article 